Reata Pharmaceuticals - RETA Stock Forecast, Price & News

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Reata Pharmaceuticals Stock Performance

NASDAQ:RETA traded down $2.44 during trading on Tuesday, reaching $21.62. 28,614 shares of the company's stock were exchanged, compared to its average volume of 269,925. The stock has a market cap of $786.97 million, a P/E ratio of -2.59 and a beta of 1.09. The company has a 50 day moving average price of $32.27 and a two-hundred day moving average price of $30.58. Reata Pharmaceuticals has a 1 year low of $20.24 and a 1 year high of $125.27.

Reata Pharmaceuticals (NASDAQ:RETA - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.90) by ($0.12). The business had revenue of $0.76 million for the quarter, compared to analysts' expectations of $1.46 million. Reata Pharmaceuticals had a negative return on equity of 137.52% and a negative net margin of 2,650.72%. The firm's quarterly revenue was down 65.7% on a year-over-year basis. During the same period last year, the firm earned ($2.00) earnings per share. Research analysts forecast that Reata Pharmaceuticals will post -8.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on RETA shares. The Goldman Sachs Group decreased their price target on shares of Reata Pharmaceuticals from $93.00 to $73.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. LADENBURG THALM/SH SH lowered their target price on Reata Pharmaceuticals from $75.00 to $67.00 in a research note on Wednesday, May 11th. Robert W. Baird reduced their price target on Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday. Finally, Citigroup boosted their price objective on Reata Pharmaceuticals from $43.00 to $46.00 and gave the stock a "buy" rating in a research report on Friday, May 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $57.57.